Antileukemic activity and mechanism of drug resistance to the marine salinispora tropica proteasome inhibitor salinosporamide A (Marizomib)

Molecular Pharmacology

Volumn 86, Issue 1, 2014, Pages 12-19

  Niewerth, Denise ^a   Jansen, Gerrit ^a   Riethoff, Lesley F V ^a   Van Meerloo, Johan ^a   Kale, Andrew J ^b   Moore, Bradley S ^b   Assaraf, Yehuda G ^c   Anderl, Janet L ^d   Zweegman, Sonja ^a   Kaspers, Gertjan J L ^a   Cloos, Jacqueline ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME; SALINOSPORAMIDE A; BORONIC ACID DERIVATIVE; LACTONE; PROTEASOME INHIBITOR; PSMB5 PROTEIN, HUMAN; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CATALYSIS; CELL GROWTH; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH; ACTINOBACTERIA; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LEUKEMIA; METABOLISM; MUTATION; TUMOR CELL LINE; UPREGULATION;

ACTINOBACTERIA; BORONIC ACIDS; CATALYSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LACTONES; LEUKEMIA; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; PYRROLES; UP-REGULATION;

EID: 84901397382     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.092114     Document Type: Article

References (40)

1. Balsas P, Galán-Malo P, Marzo I, and Naval J (2012) Bortezomib resistance in a myeloma cell line is associated to PSMb5 overexpression and polyploidy. Leuk Res 36:212-218.
2. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, and Letai A et al. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8:407-419.
3. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, and Anderson KC (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111:1654-1664.
4. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, and Anderson KC (2010) Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115:834-845.
5. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
6. de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, and Kruyt FA (2012) Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol 83:207-217.
7. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, and Fenical W (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42:355-357.
8. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, and Geerke DP et al. (2012) Impaired bortezomib binding to mutant b5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 26:757-768.
9. GrollM, Berkers CR, Ploegh HL, and Ovaa H (2006a) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14:451-456.
10. Groll M, Huber R, and Potts BCM (2006b) Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128:5136-5141.
11. Gulder TAM and Moore BS (2010) Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics. Angew Chem Int Ed Engl 49:9346-9367.
12. Huber EM, Basler M, Schwab R, Heinemeyer W, Kirk CJ, Groettrup M, and Groll M (2012) Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148:727-738.
13. Kale AJ, McGlinchey RP, Lechner A, and Moore BS (2011) Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A. ACS Chem Biol 6:1257-1264.
14. Kale AJ and Moore BS (2012) Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem 55:10317-10327.
15. Kane RC, Bross PF, Farrell AT, and Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8:508-513.
16. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, Thornberry NA, and Goldberg AL (2003) The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 278:35869-35877.
17. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, and Madden TL et al. (2012) Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120:3260-3270.
18. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, and Tiedemann RE (2013) Xbp1s-negative tumor B cells and preplasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24:289-304 Elsevier Inc.
19. Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, and Façon T et al. (2012) Sequence analysis of b-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 120:4513-4516.
20. Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, and Wang J (2008) Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 326:423-431.
21. Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, and Bostrom BC; Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium (2012) Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood 120:285-290.
22. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, and Chandra J (2007) NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROSdependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110:267-277.
23. Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, and Chandra J (2009) Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI- 0052: a mechanism for synergy in leukemia cells. Blood 113:4289-4299.
24. Niewerth D, Dingjan I, Cloos J, Jansen G, and Kaspers GJL (2013a) Proteasome inhibitors in acute leukemia. Expert Rev Anticancer Ther 13:327-337.
25. Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl JL, Schimmer AD, and Zweegman S et al. (2013b) Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica 98:1896-1904.
26. Niewerth D, Kaspers GJL, Assaraf YG, van Meerloo J, Kirk CJ, Anderl JA, Blank JL, van der Ven PM, Zweegman S, Jansen G, and Cloos J (2014a) Interferon-y-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol 7:7.
27. Niewerth D, van Meerloo J, Assaraf YG, Jansen G, Hendrickx TC, Kirk CJ, Anderl JL, Zweegman S, Cloos J, and Kaspers GJ (2014b) Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR- 924. Biochem Pharmacol 89:43-51.
28. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, and Lemos C et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112:2489-2499.
29. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, and Lu Y et al. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114: 3439-3447.
30. Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, and Broer E et al. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 160:649-659.
31. Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, and Rahemtulla A (2006) No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res 30:240-241.
32. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, and Komatsu H et al. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24:1506-1512.
33. Richardson PG, Spencer A, Cannell P, Harrison SJ, Catley L, Underhill C, Zimmerman TM, Hofmeister CC, Jakubowiak AJ, and Laubach JP et al. (2011) Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annu Meet Abstr 118:302.
34. Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft HS, Kalbacher H, and Driessen C (2009) Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23:1098-1105.
35. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, and McConkey D (2006) The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 5:1836-1843.
36. Shuqing L, Jianmin Y, Chongmei H, Hui C, and Wang J (2011) Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. Exp Hematol 39: 1117-1118.
37. Singh AV, BandiM, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, and Anderson KC (2011) PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 152:155-163.
38. van Meerloo J, Kaspers GJ, and Cloos J (2011) Cell sensitivity assays: the MTT assay. Methods Mol Biol 731:237-245.
39. Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, and Chan ET et al. (2013) Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complementdependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol 2:2.
40. Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, and Peters GJ et al. (2012) Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 341:174-182.